• 1. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

Research Brief on 2-Amino-6-chloro-3-methylbenzaldehyde (CAS: 1598290-86-8): Recent Advances and Applications in Chemical Biology and Pharmaceutical Research

2-Amino-6-chloro-3-methylbenzaldehyde (CAS: 1598290-86-8) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of pharmaceuticals and agrochemicals. Recent studies have highlighted its significance in the design of novel therapeutic agents, owing to its versatile chemical reactivity and potential as a building block for heterocyclic compounds. This research brief synthesizes the latest findings on this compound, focusing on its applications, synthetic methodologies, and biological relevance.

In the context of drug discovery, 2-amino-6-chloro-3-methylbenzaldehyde has been utilized as a precursor for the synthesis of quinazoline and benzimidazole derivatives, which exhibit a broad spectrum of pharmacological activities. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its role in the development of kinase inhibitors targeting cancer-related pathways. The compound's chloro and aldehyde functional groups enable selective modifications, facilitating the creation of libraries of small molecules for high-throughput screening.

Recent advancements in synthetic chemistry have also explored greener and more efficient routes to produce 2-amino-6-chloro-3-methylbenzaldehyde. For instance, a 2022 paper in Organic Process Research & Development reported a catalytic reductive amination process that minimizes waste and improves yield. This aligns with the pharmaceutical industry's growing emphasis on sustainable manufacturing practices. Additionally, computational studies have provided insights into the compound's reactivity, aiding in the optimization of its use in multi-step syntheses.

The biological evaluation of derivatives stemming from 2-amino-6-chloro-3-methylbenzaldehyde has revealed promising results. For example, a series of Schiff bases derived from this aldehyde displayed significant antimicrobial activity against drug-resistant strains, as documented in a 2023 European Journal of Medicinal Chemistry article. Furthermore, its incorporation into metal-organic frameworks (MOFs) has been investigated for drug delivery applications, leveraging its ability to form stable coordination complexes.

In conclusion, 2-amino-6-chloro-3-methylbenzaldehyde (CAS: 1598290-86-8) continues to be a focal point in chemical biology and pharmaceutical research. Its dual role as a synthetic intermediate and a scaffold for bioactive molecules underscores its importance in the development of next-generation therapeutics. Future research directions may include exploring its utility in covalent inhibitor design and further optimizing its synthetic accessibility to meet industrial demands.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)